

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/092546 A2

- (51) International Patent Classification⁷: **A61F 2/00** Cambridge, MA 02138 (US). JONES, Stephen, J.; 18400 Shake Boulevard, Shaker Heights, OH 44120 (US).
- (21) International Application Number: PCT/US03/13584
- (22) International Filing Date: 30 April 2003 (30.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/376,575 30 April 2002 (30.04.2002) US
- (71) Applicants: **COOK UROLOGICAL INC.** [US/US]; 750 Daniels Way, Bloomington, IN 47404 (US). **COOK BIOTECH INCORPORATED** [US/US]; 3055 Kent Avenue, West Lafayette, IN 47906 (US).
- (72) Inventors: **BOSLEY, Rodney, W., Jr.**; 4663 W. Harvest Lane, Bloomington, IN 47404 (US). **PATEL, Umesh, H.**; 1135 Kingswood Road S., West Lafayette, IN 47906 (US). **ANDREWS, Marvin, O.**; 3818 Laura Way, Bloomington, IN 47401 (US). **CHIN, Likang**; 2243 U.S. Highway 52, W#1231, West Lafayette, IN 47906 (US). **FISCHER, Frank, J., Jr.**; 4901 South Old State Road 37, Bloomington, IN 47401 (US). **RYAN, Walter, N.**; 9630 S. Lake Ridge Road, Bloomington, IN 47401 (US). **ROSENBLATT, Peter, L.**; 725 Concord Avenue, Suite 3300,
- (74) Agent: **OKEY, David, W.**; BRINKS HOFER GILSON & LIONE, P.O. Box 10087, Chicago, IL 60610 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SLING FOR SUPPORTING TISSUE

(57) Abstract: A sling for supporting a urethra in a patient has characteristics for resisting pull-out, roll-over and a combination of both pull-out and roll-over. To facilitate resistance to pull-out, sling material has protuberances or serrations to resist movement once placed in the patient by the surgeon. Improved resistance to roll-over or roll-up is achieved by providing relief on the sling in areas potentially subjected to roll-over forces by endopelvic fascia. The sling may be used on female or male patients, and may be used in conjunction with a wider support portion to support a bladder and a urethra, rather than a urethra alone. The sling may also be used to support other tissues within a patient.

WO 03/092546 A2

SLING FOR SUPPORTING TISSUE

RELATED APPLICATIONS

[0001] This application claims the benefit of the filing date under 35 U.S.C. § 119(e) of Provisional U.S. Patent Application Serial No. 60/376,575, filed on April 30, 2002, which is hereby incorporated by reference in its entirety.

BACKGROUND

[0002] Urinary incontinence arising from several conditions is a common symptom in many women, especially women who had previous vaginal deliveries. Stress urinary incontinence (SUI) is the involuntary loss of urine due to increases in intra-abdominal pressure associated with laughing, lifting, coughing, or other physical activity. SUI may be caused by excessive bladder neck mobility (hypermobility) and/or intrinsic sphincter deficiency (ISD). Bladder neck hypermobility is typically the result of weak periurethral and bladder support tissue which permits the movement of the bladder neck and proximal urethra during times of increased intra-abdominal pressure. ISD is an inherent weakness of the internal urinary sphincter due to scarring or denervation which renders the internal urinary sphincter incompetent. An incompetent urinary sphincter may allow SUI in the absence of bladder neck hypermobility as urine is pushed through the incompetent sphincter with increases in intra-abdominal pressure. Some patients have both bladder neck hypermobility and ISD resulting in extreme SUI. It is important to recognize and understand that SUI is a symptom, not a disease or disorder per se.

[0003] A variety of techniques has arisen for treating the symptom of SUI. The techniques primarily involve supporting the urethra in a position where the flow of urine may be controlled by urethral compression during increases in intra-abdominal pressure. Fig. 1 illustrates the problem. Internal parts 10 of a female include a bladder 12 and a urethra 14 leading

-2-

from the bladder. The urethra is a relatively small tubular organ leading from the bladder to the external portion of the body. Fig. 1 also illustrates the pubic bone 18 and the vagina 16. The urethra is shown in a relatively unsupported position, slumped to the right in Fig. 1, where the urethral sphincter may be unable to control the flow of urine in the patient.

[0004] Prior art techniques include a variety of ways to support the urethra. These ways include suturing to musculature or fascia beneath the urethra. Perhaps the most popular recent methods have involved placing a sling or hammock beneath the urethra, and supporting the hammock by anchoring it to fascia or other suitable supports, such as rectus muscle, the pubic bone, Cooper's ligament, or to subcutaneous tissue above the rectus fascia. Prior art slings are depicted in Figs. 2 and 3. In Fig. 2, a prior art sling 20 includes a central portion 22 and means for attaching 24, 26 on the ends of the sling. These means for attaching may include tabs as shown or may include a suture 28 to allow a surgeon to draw the ends of the sling through the patient. Fig. 3 depicts another prior art sling 30. This sling has a central portion 32 with visual indicators 34 to aid the surgeon in positioning the sling under the urethra. The sling may be tapered towards the ends 36, and also has suture receiving sites 38 to resist tearing as the surgeon extends the sling through the body of the patient.

[0005] These prior art techniques have disadvantages in that they are not necessarily stable within the body of the patient. That is, once the sling is placed, it may tend to move, and thus the patient does not receive the benefit of the surgeon's precise placement of the sling for supporting the urethra and gaining the best control over incontinence. Other disadvantages lie in the design of the sling itself. Since at least the central portion of the sling has a constant width, it may be subject to rolling or bunching under the urethra. This may tend to re-form a wide band into a narrow supporting band underneath the urethra, providing less support and possibly cutting into the urethra in extreme cases.

[0006] What is needed are improved or alternative slings or hammocks for urethral support. What is needed are slings that will remain where the surgeon places them, and which will gently and reliably support the urethra and potentially other tissue structures, allowing a patient long-term relief from stress urinary incontinence.

BRIEF SUMMARY

[0007] One aspect of the invention is a sling for supporting a urethra. The sling comprises a first end portion and a second end portion, and a support portion for supporting the urethra. There is also a first transition segment connecting the first end portion to the support portion, and a second transition segment connecting the second end portion to the support portion. At least one of the transition segments provides a relief.

[0008] Another aspect of the invention is a method for supporting a urethra in a patient. The method comprises placing a sling on either side of a urethra, the sling having a support portion, and a first portion and a second end portion connected to the support portion by transition segments, wherein the transition segment defines a relief. The method also comprises creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient. The paths are created by a method selected from the group consisting of a retrograde method and an antegrade method. The method also comprises placing the sling into the paths to anchor the sling to the patient.

[0009] Another aspect of the invention is a sling for supporting a urethra of a patient, the sling comprising a support portion, and also having a first portion and a second portion connected to the support portion. The first and second portions have serrations. Another aspect of the invention is a method for supporting a urethra in a patient. The method comprises placing a sling on either side of a urethra, the sling having a support portion, and a first portion and a second portion connected to the support portion, the first and second portions having serrations for anchoring the

-4-

sling in the patient. The method also comprises creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient. The paths are created by a method selected from the group consisting of a retrograde method and an antegrade method. The method also comprises placing the sling into the paths to anchor the sling to the patient.

[0010] Another aspect of the invention is a method for supporting tissue within a body of a patient. The method comprises placing a sling within the body, near the tissue, the sling having a support portion, and a first portion and a second portion, each connected to the support portion by a transition segment, wherein the transition segment defines a relief. The method further comprises creating a path for the first and second portions of the sling, and placing the first and second portions of the sling into the path. The method also comprises anchoring the sling. Another aspect of the invention is a method for supporting tissue within a body of a patient. The method comprises placing a sling within the body, near the tissue, the sling having a support portion, and a first portion and a second portion connected to the support portion, the first and second portions having serrations for anchoring the sling in a patient. The method further comprises creating a path for the first and second portions of the sling, and placing the first and second portions of the sling into the path. The method also comprises anchoring the sling.

[0011] There are many ways to practice the present invention, as shown in the following drawings and specification. The embodiments are not meant to limit the invention, but rather to describe and illustrate the many ways that the present invention may be used.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Fig. 1 depicts a problem urethra requiring support.

[0013] Fig. 2 represents a prior art sling for supporting a urethra.

[0014] Fig. 3 represents another prior art sling for supporting a urethra.

-5-

[0015] Fig. 4 is an embodiment of an improved sling having transitions segments according to the present invention.

[0016] Fig. 5 is another embodiment of an improved sling having serrations according to the present invention.

[0017] Figs. 6-8 are further embodiments according to Fig. 5.

[0018] Fig. 9 is another embodiment of the present invention.

[0019] Fig. 10 is a closer view of the serrations of Fig. 7.

[0020] Fig. 11 is a closer view of the sutures of Figs. 5 and 9.

[0021] Fig. 12a is a side view of a needle and handle for implanting a sling, and Fig. 12 b is a perspective view of the needle.

[0022] Fig. 13 is an isometric view of the handle of Fig. 12.

[0023] Fig. 14 is a side view of an antegrade method of implanting the sling.

[0024] Fig. 15 is a side view of a retrograde method of implanting the sling.

[0025] Fig. 16 is a cross sectional view of the sling in place under a urethra.

[0026] Figs. 17-19 are additional embodiments of a sling.

[0027] Figs. 20 and 22 are embodiments of a sling for supporting a bladder and a urethra.

[0028] Fig. 21 depicts the desired result from implanting a sling under a urethra of a patient.

[0029] Figs. 23-25 are top views of a sling having a support portion and a transition segment defining a relief.

[0030] Figs. 26-27 are cross-sectional views of a sling having a support portion and a transition segment defining a relief.

DETAILED DESCRIPTION OF THE DRAWINGS AND THE PRESENTLY PREFERRED EMBODIMENTS

[0031] The present invention provides slings with adaptations for ameliorating potential causes of pull-out or roll-over of a sling, or a

combination of pull-out and roll-over. In some cases, the problem of roll-over may be related to the support portion of the sling, since the primary consideration of this portion in most cases is to provide support for about 1-2 cm of the urethra, spreading the mechanical load and avoiding a stress concentration whereby the sling could damage the urethra. At least one contributor to roll-over forces and roll-over may be the endopelvic fascia, running near the urethra and roughly perpendicular to the sling. The sling may be implanted near the fascia, where the bulk and stiffness of the endopelvic fascia may interfere with a flat, planar installation of the sling by compressing the sling where the fascia pass through the sling. The sling may then be rolled or bunched into a narrow band under the urethra, depriving the urethra of broader, less stressful support.

[0032] To facilitate addressing this problem, embodiments of the present invention provide relief near the support portion of the sling. The relief features provide relief for any endopelvic fascia passing transversely to the orientation of the sling when implanted. Narrowing transitions for providing relief are preferably gently radiused so that the sling continues to provide maximum support for the urethra. The transitions are preferably narrower than the adjacent support portion and the left or right side "tail" or supporting portion of the sling. In addition to or as an alternative to narrower portions, relief may be effectively provided by modifying any material in the relief area to render it less resistant to deformation or displacement by surrounding patient tissues. For example, material in the relief area may be windowed, sliced, perforated or otherwise sufficiently weakened or otherwise modified to facilitate the passage of endopelvic fascia without curling or rolling the intermediate portion of the sling device.

[0033] Other features may be added to the sling to increase resistance to pull out, for example anchors that provide convoluted surfaces, surfaces that interfere with movement of the sling, thus increasing resistance to pullout or movement. The features or anchors may be protuberances such as barbs, whereby the sling is provided with a plurality of small anchors to

-7-

prevent movement once the sling is placed into a patient. In addition, or instead of barbs or protuberances, the sling may be provided with serrations on its edges, in order to resist pullout. Other features that may help in anchoring the sling include perforations in the sling, in the support portions or in the transition regions, or both. Some of these anchoring features, especially penetrations or perforations, may also help to encourage the ingrowth of bodily tissue into the sling, thus supporting and stabilizing the sling. These features may help to stabilize the sling within the patient by increasing the surface area that opposes movement within the patient's body.

[0034] The features that improve the sling are shown in the figures. Fig. 4 depicts an improved sling 40, having a support portion 42, first (left) and second (right) portions 43, 44, and transitions 45, 47 where the support portion connects to the first and second portions. In a preferred embodiment, the sling may be about 1.5 to 2 cm wide in the support portion. Other embodiments may have a width from about 8 mm to much wider if the sling is meant to support a bladder as well as a urethra. In those embodiments, the sling may be as wide as 7 cm, and the support portion may be 4 cm long. The transitions should be smoothly radiused so as not to provide sites for initiation of tears or cracks in the material. In one embodiment, the transitions may have a radius of about 2 cm, and the narrowest portion of the sling may occur in the radiused portion, the sling being as narrow as 7-8 mm at that point. The sling may be attached to a needle or other device for implanting the sling in any convenient way. In the present embodiment, tang 48 may be molded in or machined into the sling so that the sling is easily attached to a slot or an orifice in a needle. In other embodiments, a suture may be used to attach the sling to a needle.

[0035] Another embodiment features the serrations discussed above. Fig. 5 depicts an improved sling 50 having an intermediate portion 52, first (left) and second (right) portions 53, 54, with serrations 58 on both the left

and the right portions. Sling 50 also has left and right ends 55, 56, and sutures 57 attached to the left and right ends for use by a needle or other ligature carrier to implant the sling in the body of a patient. The serrated portions may be from about 10 mm wide to about 18 mm wide. The serrations may be molded into the material when it is prepared, or the serrations may be added by secondary machining or forming operations performed on the sling. The sling may be enclosed in one or more plastic sheaths 59 to ensure sterility and, in some instances, to facilitate travel of the sling through the body of the patient.

[0036] Three types of serrations have been tested on a variety of materials to determine resistance to pullout. The three types of serrations are depicted in Figs. 6-8, which depict respectively Serration I, Serration II and Serration III. Serration I may be described as the least resistive serration, with only a very gentle ridge and little difference between the "peaks" and the "troughs" of the serration. Serration II provides a much more distinct and sharp serration, almost in the form of a saw tooth, and with little relief between teeth. Serration III also provides a distinct and sharp serration, but with ample relief cut into the sling between each serration. Testing, discussed below, suggests that Serration II is the most effective of the three types, and has a significant advantage over slings with no serrations, slings with Serrations I or III, and a competitive sling that also has no serrations.

[0037] Pull-out test specimens were prepared from a variety of sling materials. Tests were conducted by inserting the sling material made of porcine small intestine submucosa (SIS) into cut surfaces of round steaks approximately 1-2 cm thick. The samples were inserted into the steak so that approximately 7 cm of each sample remained to be pulled through the steak by an Instron testing machine. The jaw of the Instron was then connected to the sling and an extension rate of about 100 mm/minute was used to pull the sling against the serrations. Maximum force was recorded as sling failure load (N). Results of the test are shown below in Table 1.

[0038]

TABLE 1

Material Type	Serration	1.1 cm width	2.0 cm width
8-layer SIS, process A	None	1.1 N	2.33 N
	Serration I	2.75	0.47
	Serration II	15.98	10.52
	Serration III	5.68	12.03
4-layer SIS Process A	Serration II	4.01	4.1
	Serration III	2.25	4.84
4-layer SIS Process B	Serration II	0.8	7.12
	Serration III	1.17	2.72
8 layer SIS process B	Serration II	6.13	8.29
	Serration III	3.3	3.4
Competitive Product	None	2.14	

[0039] Subsequent testing confirmed that the serrated edges required more force to pull through, and that an 8-layer SIS laminate required at least twice as much force as a 4-layer laminate. Although serrations are clearly effective in resisting pullout, other features may desirably be added to the sling in order to make the sling even more resistant to movement within the patient's body. These features may provide a third-dimensional aspect to the otherwise flat, almost two-dimensional slings. The features may be added during normal processing of the sling material, such as when material is vacuum-processed and pressed, and a form or mold for the material contains voids or perforations for the material to fill, thus adding a desired feature.

[0040] In some embodiments, it may be beneficial to encourage the growth of bodily tissue into the sling. Figure 7 depicts perforations 73 which have been placed into the sling in order to encourage the ingrowth of tissue. The perforations may be placed as desired, and are preferably spaced along a length of the sling for better overall support.

[0041] Processes for making multi-layer laminates from a plurality of individual layers of material are disclosed in U.S. Pat. Nos. 5,885,619 and

5,711,969, hereby incorporated by reference in their entirety. Additional teachings as to processing and layering the materials are disclosed in U.S. Pat. Nos. 5,733,337, 5,995,110, 5,993,844, 5,997,575, and 6,206,931, all of which are hereby incorporated by reference in their entirety. These patents teach the harvesting, cleansing, sterilizing and processing the submucosa from a variety of sources, including the alimentary, respiratory, urinary or genital tracts from bovine, ovine and porcine sources. Included in the processing are processes to dehydrate and compress the submucosal tissues. Processes may include vacuum drying, dead-weight pressing or other pressing, lyophilizing, room temperature or heat pressing, perforating, layering, and so on. Slings made from submucosal tissues by these and other processes are meant to be used in the present invention.

[0042] The multiple-layer embodiments may contain two laminae to eight or even more laminae of collagenous material. A preferred embodiment is a four-layer or an eight-layer material made from porcine SIS, and vacuum-pressed to bind the layer in the thickness dimension. Any numbers of methods may be used to produce laminates, including the processing described above, mechanical reinforcements in the third (thickness) dimension, and the like.

[0043] Fig. 9 depicts a sling 90 having a third-dimensional aspect added by protuberances 96 added to the surface of the material during processing. Sling 90 has a support portion 91, the support portion preferably about 2 cm wide by about 1 cm long. The support portion 91 is joined to left and right portions 92, 93 by transition or relief segments 95, wherein the narrowest portion of the sling 90 occurs in the transition segments. In a preferred embodiment, the sling may have a width of from about 6 mm to about 1.2 mm in the narrowest portions. The sling has a plurality of serrations 94 and protuberances 96 on the top surface of the sling, and may additionally or alternatively have protuberances on the

-11-

bottom surface of the sling (not shown). The sling has sutures 97 on the left and right ends 98, 99 of sling 90.

[0044] As mentioned above, the protuberances may be formed during processing of the sling material by forming the material in suitable forms or molds. In one embodiment, the protuberances are in the form of buttons or short cylinders, as shown in Fig. 9, the buttons being about 1-2 mm diameter and 1-2 mm high. Other forms or shapes may be used, including regular polygons, ellipses, or other geometrical shapes. Alternatively, the protuberances may take the form of barbs or other means for retaining position in the body of a patient. Any retaining features that will help to immobilize the sling will suffice, such as protuberances, barbs, bumps, bulges, or projections, especially in the third (height) dimension.

[0045] Fig. 10 depicts a closer view of the left end 98 of sling 90. The sling may have serrations and may also have a suture 97 joined to the sling. In one embodiment, the sling may be about 1.5 cm wide at the wide part of each serration, and may be about 10 mm wide at the narrower part of each serration. The suture is preferably joined to the sling in such a manner that the sling does not roll over or otherwise bunch up to increase resistance when the surgeon pulls the sling through the body of the patient. The suture is therefore preferably wound through the sling with a complete loop in at least two places. A preferred embodiment of a suture mounted to a sling is shown in Fig. 11. The suture 97 is first sewn through sling end 98 and then looped at least once. The suture is then sewn through sling end 98 at a second location, followed by at least one loop. More points of attachment of the suture to the sling may be made if desired. This procedure resists rollover of the sling when it is pulled through the patient's body, and also resists tear-through when the suture is attached about 2 mm from the end of the sling.

[0046] The sling may be used as a part of a kit furnished to a surgeon for inserting the sling into the body of a patient. The other components of such a kit are depicted in Figs. 12a, 12b, and 13. The

-12-

components may include a handle 121 for grasping by the surgeon, and a set-screw 124 for securing a needle 125 into the handle. The needle may have a proximal end 123 for securing into the handle by means of flats on the proximal end of the needle. The needle also has a distal end 126 with an aperture 127 for attaching the sling to the needle. The distal end 127 may also be flattened to more easily attach the sling to the needle. The handle 121 has an orifice 131 for accepting the proximal end of the needle. The set screw 124 is then used to snug the needle to the handle, preventing movement and rotation once the set screw is hand-tightened. The set screw may be made of metal or plastic. A needle tight and secure in the handle gives the surgeon a steady grip as the needle is used to implant the sling. The kit may also include a second needle, requiring cystoscopy to be performed only once during the implanting procedure.

[0047] The needle used may be a modified Stamey needle used as a ligature carrier, preferably having a curved portion. The curve is from about 50 degrees to about 75 degrees, shown in Fig. 12a as angle A. As mentioned above, a portion of the proximal end of the needle is flattened to fit into the handle, which has a rectangular aperture for receiving the needle. A portion of the distal end of the needle may also be flattened, and may have an aperture for attaching a suture or for directly attaching the sling. The sling may be directly attached if there is a tang or other attaching feature on the sling for inserting into the aperture in the distal end of the needle. Other ligature carriers may also be used, whether or not a suture is used to connect the sling to the needle.

[0048] An advantage of a kit which contains the needle and the sling as described above is that the operation for inserting the sling into the body of a female patient may be performed by either an antegrade or a retrograde method. This option is helpful, because some surgeons have only been trained to perform one of the above-mentioned procedures. In addition, due to previous procedures performed on a particular patient, it may be best to perform the operation by one technique rather than the other. As

an example, in the antegrade technique the entire needle need not pass through the body of the patient because the sling attaches to the distal end of the needle. Only enough of the needle need pass through so that the surgeon can grasp the sling, or a suture attached to the sling.

[0049] An antegrade procedure is depicted in Fig. 14. Fig. 14 depicts anatomical features in the area of interest, including the pubic bone 141, bladder 142 and urethra 148, vagina 143 and uterus 144, and rectum 145. A rigid catheter guide (not shown) is deflected to the ipsilateral side just before inserting the needle, in order to minimize the risk of bladder or urethral perforation. A needle 125 is guided from a small incision on one side of the abdomen, behind the pubic bone 141, with the surgeon maintaining close contact between the distal tip of the needle and the pubic bone in order to minimize the risk of vascular injury. When the needle is delivered into the vaginal incision, the sling, or a suture attached to the sling, is placed through the aperture in the distal end of the needle, and one portion of the sling is pulled back through the tract or space developed by the needle or ligature carrier. The procedure is then repeated on the other side. The surgeon may then adjust the sling and perform a stress test by any method deemed appropriate, such as a cough test or a Q-tip test. The sling is adjusted by the left and right ends, which are then trimmed to length at the close of the procedure, preferably just under the abdominal skin.

[0050] A retrograde procedure may also be used to place the sling. In the retrograde procedure, a vaginal incision is used, and a rigid catheter guide is deflected to the ipsilateral side just before inserting the needle, in order to minimize the risk of bladder or urethral perforation. The needle or ligature carrier is inserted into a previously developed paraurethral space and advanced slightly laterally, maintaining contact with the back of the pubic bone as much as possible to minimize the risk of vascular injury. The surgeon may remove the handle from the needle and the sling, or a suture attached to the sling, is placed through the aperture in the proximal

end of the needle, and one portion of the sling is pulled through the tract or space developed by the needle or ligature carrier. The procedure is then repeated on the opposite side.

[0051] Fig. 15 illustrates this technique using needle 120. Also depicted in Fig. 15 are anatomical features of concern during the procedure, including pubic bone 141, bladder 142 and urethra 148, vagina 143 and uterus 144, and rectum 145. In both the antegrade and retrograde methods, it is preferable to that the sling be in a hydrated condition before placement into the patient. This condition provides the sling with the proper amount of moisture for implantation into the patient. Thus, in cases where the sling is provided in a dehydrated state, it is preferable to rehydrate the sling for at least three to ten minutes, depending on the particular product used and the number of laminae in the product, prior to implantation in the patient.

[0052] Fig. 16 is a cross-sectional view of a sling in place, supporting a urethra. Sling 163 and ends 164, shown before the ends are trimmed, extend under the abdominal skin 161 to support the urethra 162. The sling extends from just under the skin 161 through the rectus fascia 165, the rectus muscle 168 and the endopelvic fascia 169. Shown also is the vaginal mucosa 166 and the vaginal wall 167 with penetrations for placement of the sling. Portions of the endopelvic fascia may be displaced by the sling, and it is this displacement that may tend to cause rolling or bunching of the sling under the urethra. The transition or radiused portions of the sling minimize this tendency and allow stable placement of the sling.

[0053] There are other embodiments of the sling that may be used to support a urethra or other organ or tissue within a body. The embodiments discussed so far have focused on flat, relatively planar slings. It is possible to add a third dimension to the sling in one or more ways. While there may be advantages related to a flat structure, the portion that supports the urethra is actually shaped into a three-dimensional structure when it is curved under the patient's urethra. Such a three-dimensional structure

may be pre-manufactured into sling devices, or sling devices may be adapted individually to suit the needs of a particular patient. The ends of the sling, whether with serrated edges or plain, may be given a third dimension by adding another plane of submucosal tissue cross-wise, as shown in Fig. 17, or by forming the ends into a corkscrew or spiral arrangement, as shown in the convoluted support portions of Fig. 18.

[0054] In Fig. 17, sling 170 has a support portion 171 and at least one end 173 connected to the support portion by relief 172. End 173 is generally flat and may have anchoring protuberances 175, such as small columns or cylinders or raised dots. Another anchoring piece 174 is molded or attached to end 173 at an angle for anchoring the end even more securely around other bodily parts. Fig. 19 provides a closer view of protuberances 194 in a sling end portion 193. These protuberances may be those depicted in Figs. 9 and 17.

[0055] Fig. 18 depicts a sling 180 with a support portion 181 attached via transition segments 182 to ends 183. Ends 183 are formed into a convoluted spiral or helical-shaped tail for anchoring the end more securely around other bodily parts. In addition, the sling 180 may have lower portions 184 and higher portions 185 formed or molded into the sling to further assist in anchoring to a patient's body. The raised or lowered portions may be similar to threads of a screw, including a regular pitch (spacing) between raised and lowered portions 184 and 185. The pitch may be from about 0.030 inches to about 0.150 inches, preferably from about 0.060 inches to about 0.100 inches.

[0056] The embodiments of Figs. 17-19 may be used in the same manner as that described above for antegrade or retrograde placement to support a urethra. Alternatively, if the sling is used to support a different organ or other soft tissue within the body, the three-dimensional ends of a sling may be anchored in any convenient way to a cooperating bone, ligament, or support that is available. The three dimensional aspect of the

slings may help to retain them in place after a surgeon places them within the patient.

[0057] The primary use of the slings discussed so far has been to support the urethra of the patient. The slings are not limited to supporting the urethra, and may be used for other purposes. For instance, by widening the support portion of the sling, it may be used to support at least a portion of a bladder as well as a urethra. A sling for this purpose is depicted in Figs. 20 and 22. In Fig. 20, sling 200 for supporting a urethra and at least a portion of a bladder has a support portion 201, and end portions 202, 204, connected to the support portion via transition segments 205. The end portions may also have serrations as discussed above to help prevent pullout or movement of the sling within the patient. Fig. 22 also depicts a sling 220 for supporting a urethra and at least part of a bladder. Support portion 221 is joined to first portion 222 on the right and to second portion 224 on the left. Serrations 226 help to retain the sling in place after a surgeon implants the sling.

[0058] Success in the implantation of a sling may produce a result in which the urethra is supported and the user is enabled to control the flow of urine in a natural manner. The desired result of a sling implanted in patient 210 is shown in Fig. 21, in which sling 212 is held in place under the urethra 216 by sling ends 214. The ends of the sling may extend around the pubic bone 218 to just under the abdomen. If the patient also needs support for the bladder, to minimize the number of implantations and procedures, both bladder and urethral support may be provided using a device similar to the one depicted in Fig. 20.

[0059] The transition segments have focused on narrowing transitions. It is also possible to provide the desired relief by transition segments in which material is perforated, sliced or otherwise weakened in specific areas to provide relief. The relief may be provided by material that has openings sliced into it, holes or windows provided, and the like. Figs. 23-25 provide embodiments of slings in which the transition segment is so

processed. Fig. 23 depicts a sling 230 having a support portion 231 and a transition segment 232 with holes 233 formed or cut into the sling material. Fig. 24 depicts a sling 240 with a support portion 241 and a transition segment with fenestrations 243 placed longitudinally in the transition segment. Fig 25 depicts a sling 250 with a support portion 251 and a transition segment 252 with ovate penetrations 253 at about a 30° angle to the length direction of the sling. Any perforations in the areas shown, as well as other areas of the sling, including the central support portion, transitions, and support arms, may also encourage ingrowth of tissue, so that the body accepts, absorbs, supports, and integrates the sling. These techniques aid in anchoring the sling in the patient.

[0060] Other embodiments of a relief are shown in Figs. 26 and 27, which show cross-sectional views of the sling. In Fig. 26, sling 260 has a support portion 261 connected to a first portion 262 via a transition segment 263. Transition segment 263 is thinner than the support segment 261 or the first portion 262. In one example, the transition segment may be made of four layers of porcine SIS while the support and other segments may be made of eight layers of porcine SIS. In Fig. 27, a sling 270 has a support portion 271 and a first portion 272 joined by a transition segment 273. In this example, the support portion 270 may comprise 8 layers of vacuum-processed porcine SIS, and the first portion 272 may comprise 6 layers of vacuum-processed porcine SIS, while the transition segment 273 comprises 4 layers of SIS material.

[0061] The sling may be made from any suitable material. Suitable collagenous materials include, but are not limited to, purified or reconstituted collagen; bovine or other mammalian pericardium; decellularized dermis; submucosa tissue such as urinary bladder submucosa, stomach submucosa, small intestine submucosa, and uterine submucosa; serosa tissue such as bovine serosa; basement membrane tissue such as liver basement membrane; autologous, allogenic or xenogenic fascia lata; and so on. Materials which constitute a collagen-

based extracellular matrix (ECM) are preferred. In general, mammalian tela submucosa tissues, which are collagen based and thus predominantly collagen, are preferred ECM materials. These tissues may be procured from the alimentary, respiratory, urinary or genital tracts of animals.

[0062] ECM materials, when used, may optionally retain growth factors or other bioactive components native to the source tissue. For example, the submucosa tissue may include one or more growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), and/or platelet derived growth factor (PDGF). As well, submucosa tissue used in the invention may include other biological materials such as heparin, heparin sulfate, hyaluronic acid, fibronectin and the like.

[0063] A preferred material is small intestine submucosa (SIS) obtained from a porcine source, although the material for the sling is not limited to this material. As mentioned above, other materials useful in slings according to the present invention are disclosed in U.S. Pat. No. 6,206,931, hereby incorporated by reference. Cross-linked ECM materials are one embodiment of materials useful in the present invention, as are materials that are not cross-linked. Cross-linked materials tend to be less bioresorbable than non-cross linked materials.

[0064] A sling may also be formed from a tissue engineered product involving cell culture techniques, such as the use of stem cell technology or using smooth muscle cells with SIS material. One such technique is to seed smooth muscle cells onto SIS material or other biodegradable scaffold. Other biodegradable scaffolds, some of which are mentioned elsewhere, include polyglycolic acid (PGA), collagen, and extra-cellular matrix materials (ECM), as well as SIS. A sling may also be formed using stem cell technology. One technique is to culture stem cells in a specific medium to induce smooth muscle differentiation. Suitable media include, but are not limited to, SIS, ECM, PGA, and collagen. The new derived

cells, formed from Stem cells, could be formed into the product or seeded onto the matrix material to form a sling.

[0065] Collagenous materials used for slings may be cross-linked with a chemical cross-linking agent, such as formaldehyde or glutaraldehyde. Other cross-linking agents that may be used include, but are not limited to aldehydes, sulfo-N-hydroxysuccinimide, polyepoxy compounds, and carbodiimides, including 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). Polyepoxy compounds may include, but are not limited to glycol diglycidyl ether, polyol polyglycidyl ether, and dicarboxylic acid diglycidyl ester. Materials for slings may also be cross-linked by radiation treatment, such as exposure to electron-beam radiation. In some instances, the strength or stiffness may in some ways be degraded by the use of electron-beam radiation. The degree of support or reinforcement necessary may determine the material used. The cross-linking lends additional strength and stiffness to materials, better enabling them to carry loads and absorb stresses. In other applications, non-cross-linked materials may suffice, and their greater flexibility and resilience may serve the patient better than a stronger, stiffer material. In addition, non-cross-linked, more bioresorbable materials are very useful in embodiments of slings useful for implantation within a human body. Slings made from any of these or other materials may also be coated with an antibacterial or an anti-inflammatory treatment to reduce infection or inflammation at the implanted sites. Slings may also be coated with an protease inhibitor to enhance tissue regeneration.

[0066] In addition to and potentially in combination with these natural materials, other natural or synthetic materials may be useful as slings or as reinforcements or additions to slings. These materials may include, but are not limited to, nylons, polyesters, polystyrene, polyethylene, polypropylene, polyacrylates, polyvinyl compounds such as polyvinyl chloride, polycarbonates, polytetrafluoroethylene, thermanox, nitrocellulose, cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin,

dextran, and the like. In some cases, bioresorbable materials may be indicated. Bioresorbable materials are those which ideally disappear after treatment without leaving a trace of their prior presence. Bioresorbable materials which may be used alone or in conjunction with ECM materials include, but are not limited to, biodegradable polyesters, polyorthoesters, polyglycolide-co-lactides, polyanhydrides, and polyesteramides. The slings for supporting soft tissues within the body may be made by any of these materials, or by a combination of these materials.

[0067] In addition to these materials for the slings themselves, a sling for repair of soft tissue in a human body may utilize a protective sheath, as mentioned above. The plastic sheaths desirably protect the sling and help maintain the sling in a sterile condition. In addition, the sheath may be used to help draw the sling through the body. Material for the sheath is preferably a smooth, frictionless plastic, such as polyethylene, but other plastics may also be used for a sheath, including but not limit to, polystyrene and polyvinyl chloride.


[0068] Attention has focused on urethral applications for these materials, particularly for female patients. As noted above, slings made from these materials may also be used on male patients, particularly males experiencing urinary disfunction after prostate surgery or other trauma to the urethral region. The slings made from these materials are not limited to supporting the urethra and the bladder, but may also be used for supporting a variety of soft tissues within the body. Slings made from these materials may be used for repair of a rectum or for paravaginal repairs, such as vault prolapse, cystocele, and enterocele. Abdominal walls may use these materials, as well as herniated tissues, prolapsed tissues, and perforated tissues. Suitable applications for herniated tissues may include abdominal, inguinal, diaphragmatic, epigastric, gastroesophageal, hiatal, intermuscular, mesenteric, paraperitoneal, rectovaginal, uterine and vesical. These materials may also be used for

general tissue repair in areas such as an anterior pelvic floor, bladder repair, thoracic walls, and the like.

[0069] The sling embodiments of the present invention may be made from one or more of the materials listed above, and may be used for any of the procedures listed herein. The slings are not limited to female urethral support, nor to male urethral support, but may be used in a variety of procedures to support bodily tissues. As mentioned above, multi-layer slings may be fashioned from multiple layers of materials in a variety of techniques in order to strengthen and stiffen the reinforcement.

[0070] It will be understood that no limitation of the scope of the invention is intended by the above description and drawings, which is defined by the claims below.

CLAIMS:

1. A sling for supporting a urethra, the sling comprising:
a first end portion and a second end portion;
a support portion intermediate the first and second end portions, for supporting the urethra;
a first transition segment connecting said first end portion to said support portion, and a second transition segment connecting said second end portion to said support portion, wherein at least one of said transition segments provides a relief.
2. The sling of Claim 1, wherein the first end portion and the second end portion are serrated.
3. The sling of Claim 1, wherein the transition segments are radiused from about 10 mm to about 25 mm and wherein the sling has a width of from about 6 to 12 mm in the transition segments.
4. The sling of Claim 1, further comprising at least one suture about 2 mm from an end of the sling. 
5. The sling of Claim 1, wherein the support portion is about 2 cm wide and about 1 cm long, and wherein the narrowing transitions are about 2 cm long.
6. The sling of Claim 2, wherein the serrated portions are from about 10 mm to about 18 mm wide.
7. The sling of Claim 1, wherein the sling is made from at least one layer of vacuum-processed SIS.
8. The sling of Claim 1, wherein the sling is made from at least one material selected from the group consisting of synthetic materials, SIS, cross-linked extra-cellular materials, non-cross-linked extra-cellular

materials, tissue engineered materials, polyglycolic acid, collagen, and bioresorbable materials.

9. The sling of Claim 1, further comprising an anchor in the first transition segment and an anchor in the second transition segment, the anchor comprising a hole, a penetration, a serration, a protuberance, a barb, a convoluted surface, or a raised portion.

10. The sling of Claim 1, wherein the support portion is about 4 cm wide and about 7 cm long, for supporting the urethra and a bladder of the patient.

11. The sling of Claim 1, wherein at least one of the left portion and the right portion further comprises a protuberance, a button, or a tang for attaching to a needle.

12. The sling of Claim 1, wherein at least one of the first end portion and the second end portion is configured as a three-dimensional anchor in the patient.

13. The sling of Claim 1, further comprising a plastic sheath for the sling.

14. A combination of the sling of Claim 1, at least one needle having a curved portion from about 50 degrees to about 75 degrees, and a handle, wherein the at least one needle is secured to the handle with a transverse set screw.

15. The sling of Claim 1, further comprising at least one of an antibacterial treatment, an anti-inflammatory treatment, and a protease inhibitor.

16. The sling of Claim 1, wherein the sling retains at least one bio-active component native to the source tissue.

-24-

17. The sling of Claim 16, wherein the at least one bio-active component is a growth factor.

18. The sling of Claim 17, wherein the growth factor is selected from the group consisting of FGF-2, TGF-beta, EGF, and PDGF.

19. The sling of Claim 1, wherein the relief is provided by material in the first and second transition segments that has been sliced, cut out, windowed or thinned.

20. A method of supporting a urethra and a bladder of a patient, the method comprising:

placing a sling on either side of the urethra and under at least a portion of the bladder, the sling having a support portion and also having a first portion and a second portion, each connected to the support portion by a narrowing transition, wherein the narrowing transition is narrower than the adjacent support portion and the first and second portions, and wherein the support portion is about 4 cm wide and about 7 cm long;

creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient, wherein the path is created via a method selected from the group consisting of a retrograde method and an antegrade method; and

extending the sling through the paths to anchor the sling to the patient.

21. A sling for supporting a urethra of a patient, the sling comprising:

a support portion; and

a first portion and a second portion connected to the support portion, wherein the first portion and second portion have serrations.

22. The sling of Claim 21, wherein the first portion and the second portion are each connected to the support portion by a transition segment, wherein at least one of the transition segments defines a relief.

23. The sling of Claim 22, wherein at least one transition segment is radiused from about 10 mm to about 25 mm and wherein the sling has a width of from about 6 to 12 mm in the transitions.

24. The sling of Claim 21, further comprising at least one suture about 2 mm from an end of the sling.

25. The sling of Claim 22, wherein the support portion is about 2 cm wide and about 1 cm long, and wherein the transition segments are about 2 cm long.

26. The sling of Claim 21, wherein the serrated portions are from about 10 mm to about 18 mm wide.

27. The sling of Claim 21, wherein the sling is made from at least one layer of submucosa.

28. The sling of Claim 21, wherein the sling is made from at least one material selected from the group consisting of synthetic materials, SIS, cross-linked extra-cellular materials, non-cross-linked extra-cellular materials, tissue-engineered materials, polyglycolic acid, collagen, and bioresorbable materials.

29. The sling of Claim 21, further comprising an anchor in each portion of the sling, the anchor selected from the group consisting of a hole, a penetration, a barb, a protuberance, and a raised portion.

30. The sling of Claim 21, wherein the support portion is about 4 cm wide and about 7 cm long, for supporting the urethra and a bladder of the patient.

-26-

31. The sling of Claim 21, wherein at least one of the first portion and the second portion further of a protuberance, a button, and a tang.

32. The sling of Claim 21, wherein at least one of the first portion and the second portion is configured as a three-dimensional sling.

33. The sling of Claim 21, further comprising a plastic sheath for the sling.

34. A combination of the sling of Claim 21, at least one needle having a portion curved from about 50 degrees to about 75 degrees, and a handle, wherein the at least one needle is secured to the handle with a transverse set screw.

35. The sling of Claim 21, further comprising at least one of an antibacterial treatment, an anti-inflammatory treatment, and a protease inhibitor.

36. The sling of Claim 21, wherein the sling retains at least one bio-active component native to the source tissue.

37. The sling of Claim 36, wherein the at least one bio-active component is a growth factor.

38. The sling of Claim 37, wherein the growth factor is selected from the group consisting of FGF-2, TGF-beta, EGF, and PDGF.

39. The sling of Claim 22, wherein the relief is provided by transition segments that are sliced, cut out, windowed, perforated or thinned.

-27-

40. A method of supporting a urethra and a bladder of a patient, the method comprising:

placing a sling on either side of the urethra and under at least a portion of the bladder, the sling having a support portion, and also having a first portion and a second portion connected to the support portion, wherein the first and second portions have serrations, and wherein the support portion is about 4 cm wide and about 7 cm long;

creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient, wherein the path is created via a method selected from the group consisting of a retrograde method and an antegrade method; and

extending the sling through the paths to anchor the sling to the patient.

41. A method for supporting tissue within a body of a patient, the method comprising:

placing a sling near the tissue, the sling having a support portion and also having a first portion and a second portion, each connected to the support portion by a transition segment, wherein at least one of the transition segments defines a relief ;

creating a path for the first and second portions of the sling;

placing the first and second portions of the sling into the path; and
anchoring the sling.

42. The method of Claim 41, further comprising rehydrating the sling before placing the sling near the soft tissue.

43. A sling for supporting tissue within a body, the sling comprising:

a support portion; and

a first portion and a second portion, each connected to the support portion by a transition segment, wherein at least one of the transition segments provides a relief.

44. The sling of Claim 43, wherein the first portion and the second portion are serrated.

45. The sling of Claim 43, wherein at least one of the transition segments is radiused from about 10 mm to about 25 mm and wherein the sling has a width of from about 6 to 12 mm in the transition segments.

46. The sling of Claim 43, further comprising at least one suture about 2 mm from an end of the sling.

47. The sling of Claim 43, wherein the portions having serrations are from about 10 mm to about 18 mm wide.

48. The sling of Claim 43, wherein the sling is made from at least one layer of vacuum-processed SIS.

49. The sling of Claim 43, wherein the sling is made from at least one material selected from the group consisting of synthetic materials, SIS, cross-linked extra-cellular materials, non-cross-linked extra-cellular materials, tissue-engineered materials, polyglycolic acid, collagen, and bioresorbable materials.

50. The sling of Claim 43, further comprising at least one of an antiinflammatory treatment, an antibacterial treatment, and a protease inhibitor.

51. The sling of Claim 43, further comprising anchors in the sling, the anchors selected from the group consisting of serrations, perforations, barbs and raised portions.

52. A method for supporting tissue within a body of a patient, the method comprising:

placing a sling having a support portion near the tissue, the sling having a first portion and a second portion connected to the support portion, wherein the first and second portions have serrations;
creating a path for the first and second portions of the sling;
placing the first and second portions of the sling into the path; and
anchoring the sling.

53. The method of Claim 52, further comprising rehydrating the sling before placing the sling near the soft tissue.

54. A sling for supporting tissue within a body, the sling comprising:

a support portion; and
a first portion and a second portion, wherein the first and second portions each has an anchor.

55. The sling of Claim 54, wherein the first and second portions are connected to the support portion by transition segments, at least one of the transitions segments providing a relief.

56. The sling of Claim 55, wherein the transition segments are radiused from about 10 mm to about 25 mm and wherein the sling has a width of from about 6 to 12 mm in the transition segments.

57. The sling of Claim 54, further comprising at least one suture about 2 mm from an end of the sling.

58. The sling of Claim 54, wherein the anchor comprises a serration, a perforation, a penetration, a barb, a convoluted surface, or a raised portion.

59. The sling of Claim 54, wherein the sling is made from at least one layer of submucosa.

60. The sling of Claim 54, wherein the sling is made from at least one material selected from the group consisting of synthetic materials, SIS, cross-linked extra-cellular materials, non-cross-linked extra-cellular materials, tissue engineered materials, polyglycolic acid, collagen, and bioresorbable materials.

61. The sling of Claim 54, wherein the anchor is a serration, and the serrated portions are from about 10 mm to about 18 mm wide.

62. The sling of Claim 54, further comprising a plastic sheath for the sling.

63. A method of supporting a urethra and a bladder of a male patient, the method comprising:

placing a sling on either side of the urethra and under at least a portion of the bladder, the sling having a support portion and also having a first portion and a second portion, each connected to the support portion by a transition segment, wherein the transition segments define a relief, and wherein the support portion is about 4 cm wide and about 7 cm long;

creating a path on either side of the urethra for placing the first and second portions of the sling; and

placing the sling into the path to anchor the sling to the patient.

64. A method of supporting a urethra and a bladder of a male patient, the method comprising:

placing a sling on either side of the urethra and under at least a portion of the bladder, the sling having a support portion, and also having a first portion and a second portion connected to the support portion, wherein the first and second portions have serrations, and wherein the support portion is about 4 cm wide and about 7 cm long;

creating a path on either side of the urethra for placing the first and second portions of the sling; and

placing the sling into the path to anchor the sling to the patient.

65. A sling for supporting a urethra alone or in combination with a bladder of a patient, comprising:

a collagenous body having a first extension, a second extension, and a support portion intermediate the first and second extensions.

66. The sling of claim 65, wherein the collagenous body comprises an extracellular matrix material.

67. The sling of claim 66, wherein the extracellular matrix material comprises submucosa or basement membrane tissue.

68. The sling of claim 65, wherein the collagenous body comprises submucosa tissue.

69. The sling of claim 68, wherein the submucosa tissue is small intestinal submucosa tissue.

70. The sling of claim 69, wherein the small intestinal submucosa tissue is porcine.

71. The sling of claim 65, wherein the sling retains at least one bio-active component native to the source tissue.

72. The sling of claim 65, wherein the first extension and the second extension each has an anchor.

73. The sling of claim 72, wherein the anchor comprises a convoluted surface, a serration, a protruberance, a penetration, a barb, a hole or a raised portion.

74. A method of supporting a urethra in a patient, the method comprising:

placing the sling on either side of the urethra, the sling having a support portion and also having a first portion and a second portion, each connected to the support portion by a transition segment, wherein at least one of the transition segments defines a relief;

creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient, wherein the path is created via a method selected from the group consisting of a retrograde method and an antegrade method; and

extending the sling through the paths to anchor the sling to the patient.

75. The method of Claim 74, wherein the paths are created by using a needle having a portion curved from about 50 degrees to about 75 degrees.

76. The method of Claim 74, wherein the sling is extended through the paths with a needle attached to the sling by a means selected from the group consisting of a suture and a portion of the sling for attaching to the needle.

77. The method of Claim 74, further comprising adjusting the sling position within the patient.

78. A method of supporting a urethra in a patient, the method comprising:

placing a sling on either side of the urethra, the sling having a support portion and also having a first portion and a second portion connected to the support portion, wherein the first portion and second portion have serrations for anchoring the sling in the patient;

creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient, wherein the path is created via a method selected from the group consisting of a retrograde method and an antegrade method; and
extending the sling through the paths to anchor the sling to the patient.

79. The method of Claim 78, wherein the paths are created by using a needle having a portion curved from about 50 degrees to about 75 degrees.

80. The method of Claim 78, wherein the sling is extended through the paths with a needle attached to the sling by a means selected from the group consisting of a suture and a portion of the sling for attaching to the needle.

81. The method of Claim 78, further comprising adjusting the sling position within the patient.

FIG. 1




FIG. 2

PRIOR ART




FIG. 3

PRIOR ART




FIG. 4




FIG. 5




FIG. 6





FIG. 7



FIG. 8



FIG. 9



4/8

FIG. 10




FIG. 11




FIG. 12a




FIG. 12b





FIG. 13



5/8

FIG. 14




FIG. 15




FIG. 16

6/8




FIG. 17




FIG. 18




FIG. 19

7/8




FIG. 20

200




FIG. 22

220





FIG. 21

210



8/8

FIG. 23




FIG. 24




FIG. 25




FIG. 26





FIG. 27



(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 2003/092546 A3

- (51) International Patent Classification⁷: **A61F 2/00** (74) Agent: OKEY, David, W.; BRINKS HOFER GILSON & LIONE, P.O. Box 10087, Chicago, IL 60610 (US).
- (21) International Application Number:
PCT/US2003/013584 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 30 April 2003 (30.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/376,575 30 April 2002 (30.04.2002) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants: **COOK UROLOGICAL INC.** [US/US]; 750 Daniels Way, Bloomington, IN 47404 (US). **COOK BIOTECH INCORPORATED** [US/US]; 3055 Kent Avenue, West Lafayette, IN 47906 (US).
- (72) Inventors: **BOSLEY, Rodney, W., Jr.**; 4663 W. Harvest Lane, Bloomington, IN 47404 (US). **PATEL, Umesh, H.**; 1135 Kingswood Road S., West Lafayette, IN 47906 (US). **ANDREWS, Marvin, O.**; 3818 Laura Way, Bloomington, IN 47401 (US). **CHIN, Likang**; 2243 U.S. Highway 52, W#1231, West Lafayette, IN 47906 (US). **FISCHER, Frank, J., Jr.**; 4901 South Old State Road 37, Bloomington, IN 47401 (US). **RYAN, Walter, N.**; 9630 S. Lake Ridge Road, Bloomington, IN 47401 (US). **ROSENBLATT, Peter, L.**; 725 Concord Avenue, Suite 3300, Cambridge, MA 02138 (US). **JONES, Stephen, J.**; 18400 Shake Boulevard, Shaker Heights, OH 44120 (US).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
6 May 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SLING FOR SUPPORTING TISSUE



(57) Abstract: A sling for supporting a urethra in a patient has characteristics for resisting pull-out, roll-over and a combination of both pull-out and roll-over. To facilitate resistance to pull-out, sling material has protuberances or serrations to resist movement once placed in the patient by the surgeon. Improved resistance to roll-over or roll-up is achieved by providing relief on the sling in areas potentially subjected to roll-over forces by endopelvic fascia. The sling may be used on female or male patients, and may be used in conjunction with a wider support portion to support a bladder and a urethra, rather than a urethra alone. The sling may also be used to support other tissues within a patient.

INTERNATIONAL SEARCH REPORT

International Application No

PC 03/13584

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 110 101 A (RYDELL MARK A ET AL) 29 August 2000 (2000-08-29) column 3, lines 41,42; figure 1	1-19, 43-51
A	US 5 934 283 A (WILLEM GERMAIN E ET AL) 10 August 1999 (1999-08-10) column 5, line 4 - line 8; figure 3	1-19, 43-51
A	WO 00/74613 A (ETHICON INC) 14 December 2000 (2000-12-14) figure 2D	1
A	WO 98/35632 A (BOSTON SCIENT IRELAND LTD ;GELLMAN BARRY N (US); MARTIN WILLIAM (U) 20 August 1998 (1998-08-20) figure 1	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 2003

Date of mailing of the international search report

24 02. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Korth, C-F

INTERNATIONAL SEARCH REPORT

International application No.
● PCT/US 03/13584

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20, 40-42, 52, 53, 63, 64, 74-81
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:
1-19, 43-51

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 20,40-42,52,53,63,64,74-81

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-19,43-51

2. claims: 21-33,54-62

3. claims: 34-39

4. claims: 65-73

INTERNATIONAL SEARCH REPORT

International Application No

PCT/S 03/13584

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6110101	A	29-08-2000	US 6042536 A EP 1065992 A1 WO 0009039 A1 TW 450800 B	28-03-2000 10-01-2001 24-02-2000 21-08-2001
US 5934283	A	10-08-1999	NONE	
WO 0074613	A	14-12-2000	US 6475139 B1 AU 4710500 A AU 5315300 A AU 5465900 A BR 0011726 A CA 2376278 A1 CA 2376281 A1 CA 2376282 A1 CN 1409625 T CN 1433288 T EP 1200011 A1 EP 1194091 A1 JP 2003523786 T JP 2003501144 T JP 2004500152 T WO 0074594 A1 WO 0074613 A1 WO 0074633 A2 US 2002188169 A1 US 2003023138 A1 US 2003149440 A1 US 6273852 B1 US 2002077526 A1 US 2001049467 A1	05-11-2002 28-12-2000 28-12-2000 28-12-2000 05-08-2003 14-12-2000 14-12-2000 14-12-2000 09-04-2003 30-07-2003 02-05-2002 10-04-2002 12-08-2003 14-01-2003 08-01-2004 14-12-2000 14-12-2000 14-12-2000 12-12-2002 30-01-2003 07-08-2003 14-08-2001 20-06-2002 06-12-2001
WO 9835632	A	20-08-1998	AU 6329598 A CA 2280814 A1 DE 69808614 D1 DE 69808614 T2 EP 0983033 A1 JP 2001511685 T US 6042534 A WO 9835632 A1	08-09-1998 20-08-1998 14-11-2002 18-06-2003 08-03-2000 14-08-2001 28-03-2000 20-08-1998